Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Evelyn Acuña Cruz, MD, Jimena Cannata Ortiz, MD, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz Sáez, MD

Blood (2015) 126 (23): 5106.

https://doi.org/10.1182/blood.V126.23.5106.5106

Published: 2015

Journal Articles

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Jimena Cannata-Ortiz, MD, Concepción Nicolás, MD, Ana García-Noblejas, MD, Javier Lopez, Pilar Sabin, Pilar Zamora, Maria José Requena, Reyes Arranz, MD PhD

Blood (2014) 124 (21): 4465.

https://doi.org/10.1182/blood.V124.21.4465.4465

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Blood (2014) 124 (21): 3980.

https://doi.org/10.1182/blood.V124.21.3980.3980

Published: 2014

Journal Articles

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Miriam González-Pardo, Carlos Fernández-Arandojo, Jimena Cannata, Beatriz Aguado, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz, MD PhD

Blood (2014) 124 (21): 5897.

https://doi.org/10.1182/blood.V124.21.5897.5897

Published: 2014

Journal Articles

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),

Blood (2011) 118 (21): 3654.

https://doi.org/10.1182/blood.V118.21.3654.3654

Published: 2011

Journal Articles

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Ana García-Noblejas, MD, Belén Navarro Matilla, MD, Carolina Da Silva Rodriguez, Raquel De Oña Navarrete, MD, María José Ramirez Sánchez, MD, Concepción Nicolás, MD, Ricardo Pérez Fernández, Blanca Sanchez Gonzalez, MD, Eva Domingo-Domènech, MD, Jose Javier Sanchez Blanco, MD, Jimena Cannata-Ortiz, MD, Tomás José González-López, MD, Reyes Arranz Sáez, MD, PhD

Blood (2011) 118 (21): 4942.

https://doi.org/10.1182/blood.V118.21.4942.4942

Published: 2011

Journal Articles

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Jimena Cannata-Ortiz, Concepción Nicolás, Ana García-Noblejas, Javier Lopez, Maria José Requena, Concepción Alaez, Adrian Alegre, Reyes Arranz

Blood (2010) 116 (21): 2867.

https://doi.org/10.1182/blood.V116.21.2867.2867

Published: 2010

Journal Articles

Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas

Santiago Montes-Moreno, Giovanna Roncador, Lorena Maestre, Nerea Martínez, Lydia Sanchez-Verde, Francisca I. Camacho, Jimena Cannata, Jorge L. Martinez-Torrecuadrada, Yulei Shen, Wing C. Chan, Miguel A. Piris

Blood (2008) 111 (1): 351–358.

https://doi.org/10.1182/blood-2007-06-094151

Published: 2008

Journal Articles

Adult Langerhans’ Cell Histiocitosis (LCH). A Single Institution Experience.

Luis Fayad, MD, Jimena Cannata, MD

Blood (2006) 108 (11): 3890.

https://doi.org/10.1182/blood.V108.11.3890.3890

Published: 2006

Journal Articles

Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).

Francisca I. Camacho, MD, Reyes Arranz-Saez, MD, Alessia Caleo, MD, Jimena Cannata, MD, Laura Cereceda, Leocricia Gonzalez, MD, Mª Elena Perez-Martin, MD, Lydia Sanchez-Verde, PhD, Carlos Montalban, MD, Juan F. Garcia, MD, Miguel A. Piris, MD, Carmen Bellas, PhD

Blood (2004) 104 (11): 2266.

https://doi.org/10.1182/blood.V104.11.2266.2266

Published: 2004

Journal Articles

Manteinance Treatment with Interferon (IFN) Is Not Necessary to Achieve Prolonged Progression Free Survival (PFS) in Patients with Indolent Non Hodgkin’s Lymphoma (NHL). Results from a Prospective Randomized Trial on 165 Patients.

Jimena Cannata, Ph, Concepcion Nicolas, PhD, Raul Cordoba Resident, Ph, Consuelo Rayon, PhD, Jose Garcia-Laraña, PhD, Javier Lopez, Ph, Guillermo Perez, Ph, Pedro Sanchez-Godoy, PhD, Pilar Garcia-Alfonso, PhD, Pilar Zamora, Ph, Jose-Maria Fernandez-Rañada, PhD, Reyes Arranz, PhD

Blood (2004) 104 (11): 1392.

https://doi.org/10.1182/blood.V104.11.1392.1392

Published: 2004

NARROW

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas

Adult Langerhans’ Cell Histiocitosis (LCH). A Single Institution Experience.

Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).

Manteinance Treatment with Interferon (IFN) Is Not Necessary to Achieve Prolonged Progression Free Survival (PFS) in Patients with Indolent Non Hodgkin’s Lymphoma (NHL). Results from a Prospective Randomized Trial on 165 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only